miR-125b directly target STARD13 mRNA.

<p>(A) MiR-125b directly target human STARD13. (A) The miR-125b targets on STARD13 were predicted using Targetscan 5.1. (A) pMiR-Report vectors containing the wt or mut miR-125b binding site from the 3′UTR of STARD13 mRNA, and miR-125b-mimics or NC, as well as an expression cassette for Rluc were co-transfected into HEK-293T cells. Two days later Fluc activity in cells was measured and normalized to Rluc activities two days after. Data were present as the mean ± SEM, n = 3, *p<0.05 vs. NC group. (C) Breast cancer cell lines of MCF-7 and MDA-MB-231 cells were transfected with miR-mimics, miR-125b-inhibitors and control miRNA, the gene expression of STARD13 was detected by real-time RT-PCR after 48 h. Data were present as the mean ± SEM, n = 3 ^ΔΔp<0.001 NC group in MDA-MB-231 vs. NC group in MCF-7; (D) Breast cancer cell lines of MCF-7 and MDA-MB-231 cells were transfected with miR-mimics, miR-125b-inhibitors and control miRNA, STARD13 protein and β-actin after 72 h were detected by western blot. (E) Quantitative data of densitometric analyses. The ratio of STARD13 protein and mRNA levels to β-actin and GAPDH were displayed as mean ± SEM, n = 3, *p<0.05, **p<0.01 vs. NC group; ^ΔΔp<0.001 NC group in MDA-MB-231 vs. NC group in MCF-7.